C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
← catalyst calendarNCT06868264 · readout ≤ 41 d
Sponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
880estimated
Sites
105
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-07 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HEPATITIS C VIRUS CHRONIC INFECTION
Interventions
- Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR)
- Drug: Sofosbuvir-Velpatasvir (SOF/VEL)
Primary outcome
what the primary-completion date above is the date OFProportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.
measured Day 1 through Week 24
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed